toripalimab,gemcitabine,cisplatin
Shanghai Junshi Bioscience,Coherus
['toripalimab', '$chrs']
$chrs #asco23 toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, hr=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients no treatments are approved for npc in the us; if approved, toripalimab will address a critical unmet need 
BIOTECH man LONGTERM FOCUS many positions-also trade around my CORE holdings my opinion only do your own research with me